Summit Therapeutics Inc. Cash Flows From Used In Operating Activities
Summit Therapeutics Inc. (SMMT) reported Cash Flows From Used In Operating Activities of -GBP 6.70 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Cash Flow › Operating Activities
ifrs-full:CashFlowsFromUsedInOperatingActivities · last filed 2020-06-02
- Summit Therapeutics Inc. cash flows from used in operating activities for the quarter ending 2020-03-31 was -6.70M GBP, a 580.43% decline year-over-year.
- Summit Therapeutics Inc. cash flows from used in operating activities for the quarter ending 2019-10-31 was -6.28M GBP.
- Summit Therapeutics Inc. cash flows from used in operating activities for the quarter ending 2019-07-31 was -8.32M GBP.
- Summit Therapeutics Inc. cash flows from used in operating activities for the quarter ending 2019-04-30 was 1.40M GBP.
| Period end | Cash Flows From Used In Operating Activities 3 month | Cash Flows From Used In Operating Activities 3 month as first filed | Cash Flows From Used In Operating Activities 6 month | Cash Flows From Used In Operating Activities 6 month as first filed | Cash Flows From Used In Operating Activities 9 month | Cash Flows From Used In Operating Activities 9 month as first filed | Cash Flows From Used In Operating Activities 11 month | Cash Flows From Used In Operating Activities 12 month | Cash Flows From Used In Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | -6.70M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-12-31 | -15.67M GBP 20-F · filed 2020-04-30 | ||||||||
| 2019-10-31 | -6.28M GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | -14.60M GBP derived: sum of 2 quarters · filed 2019-12-17 | -13.21M GBP 6-K · filed 2019-12-17 | ||||||
| 2019-07-31 | -8.32M GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | -6.93M GBP 6-K · filed 2019-10-11 | |||||||
| 2019-04-30 | 1.40M GBP 6-K · filed 2019-06-12 | ||||||||
| 2019-03-31 | -8.10M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-01-31 | -4.53M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -8.82M GBP derived: sum of 2 quarters · filed 2020-04-30 | -19.71M GBP derived: sum of 3 quarters · filed 2020-04-30 | -26.66M GBP 20-F · filed 2020-04-30 | -26.80M GBP 20-F · filed 2019-03-29 | ||||
| 2018-10-31 | -4.29M GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | -15.18M GBP derived: sum of 2 quarters · filed 2019-12-17 | -22.14M GBP 6-K · filed 2019-12-17 | -22.38M GBP 6-K · filed 2018-12-11 | -27.78M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-07-31 | -10.89M GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | -17.84M GBP 6-K · filed 2019-10-11 | -18.00M GBP 6-K · filed 2018-09-20 | -23.49M GBP derived: sum of 3 quarters · filed 2020-04-30 | -33.93M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-04-30 | -6.96M GBP 6-K · filed 2019-06-12 | -7.04M GBP 6-K · filed 2018-06-05 | -12.60M GBP derived: sum of 2 quarters · filed 2020-04-30 | -23.04M GBP derived: sum of 3 quarters · filed 2020-04-30 | -13.54M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-01-31 | -5.64M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -16.09M GBP derived: sum of 2 quarters · filed 2020-04-30 | -6.59M GBP derived: sum of 3 quarters · filed 2020-04-30 | -14.54M GBP 20-F · filed 2020-04-30 | -14.69M GBP 20-F · filed 2018-04-13 | ||||
| 2017-10-31 | -10.44M GBP derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11 | -944.00K GBP derived: sum of 2 quarters · filed 2018-12-11 | -8.90M GBP 6-K · filed 2018-12-11 | ||||||
| 2017-07-31 | 9.50M GBP derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20 | 1.55M GBP 6-K · filed 2018-09-20 | |||||||
| 2017-04-30 | -7.95M GBP 6-K · filed 2018-06-05 | ||||||||
| 2017-01-31 | 12.14M GBP 20-F · filed 2019-03-29 | ||||||||
| 2016-01-31 | -17.18M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |